This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Does Simvastatin Affect Insulin Sensitivity in Dyslipidemic Type 2 Diabetic Patients?

This study has been completed.
Austrian Science Fund (FWF)
European Foundation for the Study of Diabetes
EU grant
Merck Sharp & Dohme Corp.
Information provided by:
Medical University of Vienna Identifier:
First received: June 23, 2008
Last updated: NA
Last verified: June 2008
History: No changes posted
We aimed to address the issue whether statins affect insulin resistance. To this end, we combined the available state-of-the art technology for detailed assessment of both whole-body and tissue specific insulin sensitivity in vivo in humans (euglycemic-hyperinsulinemic clamp, stable isotope [6,6-2H2]glucose dilution technique, proton nuclear magnetic resonance spectroscopy - 1H MRS - of liver and skeletal muscle). Outcome measures were determined before and after 8 weeks therapy with 80 mg Simvastatin in hypercholesterolemic patients with type 2 diabetes.

Condition Intervention
Hypercholesterolemia Diabetes Cardiovascular Disease Drug: Simvastatin Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Effects of High Dose Simvastatin Therapy on Glucose Metabolism and Ectopic Lipid Deposition in Non-Obese Type 2 Diabetic Patients

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • insulin sensitivity [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • ectopic lipid deposition in liver and muscle [ Time Frame: 8 weeks ]

Enrollment: 20
Study Start Date: October 2002
Study Completion Date: July 2005
Primary Completion Date: July 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Simvastatin therapy, 80 mg/d for 8 weeks
Drug: Simvastatin
80 mg Simvastatin daily for 8 weeks
Other Name: Zocord
Placebo Comparator: 2
Placebo, one pill daily for 8 weeks
Drug: Placebo
The placebo was identical in appearance and was provided by the same manufacturer


Ages Eligible for Study:   21 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetic patients with known duration of disease: 3-10 years
  • Age: 35-75 years
  • BMI<32 kg/m2
  • Hypercholesterolemia: fasting serum low density lipoprotein (LDL)
  • Cholesterol concentration < 4.16 mmol/L (<160 mg/dl)
  • Normotriglyceridemia: fasting plasma triglyceride concentration < 2.75 mmol/L (250 mg/dl)
  • Creatinine levels < 1.8 mg /dl
  • Liver transaminases < 20% over the upper limit with no active liver disease and CK < 50% above the upper limit
  • Blood pressure less than 160/100 mmHg were accepted as eligible for enrollment

Exclusion Criteria:

  • Hypertension, cardiovascular disease or metabolic diseases other than T2DM as determined by medical history, physical examination and routine laboratory tests
  • Alcohol consumption (more than 10 drinks/week)
  • Poor glycemic control (HbA1c<9%)
  • Patients requiring insulin, patients with type 1 diabetes
  • Patients taking any medicine known to interfere with metabolism of statins or with insulin sensitivity as summarized in an exclusionary drug table
  • Patients receiving any hypolipidemic medication or diet during the last 2 months before enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00704314

Medical University of Vienna
Vienna, Austria, A-1090
Sponsors and Collaborators
Medical University of Vienna
Austrian Science Fund (FWF)
European Foundation for the Study of Diabetes
EU grant
Merck Sharp & Dohme Corp.
Principal Investigator: Werner Waldhäusl, Prof, MD Medical University of Vienna
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Prof. Dr. Werner Waldhäusl, Prof. Dr. Michael Roden, Hanusch Hospital, 1. Medical Department, Vienna Austria Identifier: NCT00704314     History of Changes
Other Study ID Numbers: EK: 258/2002
Study First Received: June 23, 2008
Last Updated: June 23, 2008

Keywords provided by Medical University of Vienna:
Insulin resistance
Muscle and liver triglycerides

Additional relevant MeSH terms:
Cardiovascular Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors processed this record on August 18, 2017